3000-Patient study aims to predict PBC outcomes from blood tests
NCT ID NCT07449793
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 3,000 people with primary biliary cholangitis (PBC) to see how their blood levels of alkaline phosphatase (ALP) after treatment relate to their risk of liver complications. The goal is to create a model that predicts who will do well and who might need stronger treatment. Participants are already taking standard medication (UDCA) and will be followed over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
RenJi Hospital
RECRUITINGShanghai, Shanghai Municipality, 200001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common cholesterol drug help manage a rare liver disease?
- Artificial intelligence may help decide who gets a liver first
- AI may outsmart current system for liver transplant priority
- One pill may tame both itchy skin and stubborn liver disease
- Can a smartwatch help manage a rare liver disease? stanford study investigates
- New study tracks blood sugar in liver disease patients on common drug